Trial · NCT07908420
Accelerated Dual-Protocol rTMS for Refractory Trigeminal Neuralgia
NCT07908420, Completed, Galileo Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Accelerated Dual-Protocol rTMS for Refractory Trigeminal Neuralgia. Trials, record NCT07908420. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908420
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Accelerated Dual-Protocol rTMS for Refractory Trigeminal Neuralgia
- NCT number
- NCT07908420
- Status
- Completed
- Enrollment
- 192 participants, actual
- Lead sponsor
- Galileo Medical Center
- Conditions
- Pain Management, Psychiatric Comorbidities
- First posted
- 2026-11-02
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Patient-Reported Facial Pain Intensity via the Visual Analog Scale (VAS) | Baseline (T₀, prior to the first rTMS session) and 1-Month Post-Treatment (T₂, exactly 30 days after the final rTMS session). | The primary efficacy endpoint is the sub-acute reduction of self-reported facial pain intensity. Pain is measured using a standardized 100 mm Visual Analog Scale (VAS), where 0 represents "No Pain," and 100 represents "The Worst Imaginable Pain." Patients draw a vertical line indicating their average pain over the preceding 24 hours. The distance is measured in millimeters to provide a continuous numeric value. |
| Primary | Long-Term Durability of Analgesia via the Visual Analog Scale (VAS) | Baseline (T₀) and 3-Months Post-Treatment (T₃, exactly 90 days after the final rTMS session). | This measure tracks the persistence of the therapeutic effect or any potential neuroplastic decay over time. It evaluates if the dual-frequency accelerated paradigm sustains a statistically valid reduction in pain scores into the third month following the intervention. |
| Secondary | Change from Baseline in Pain Interference and Distribution via the Brief Pain Inventory | Baseline (T₀), Immediate Post-Treatment (T₁, Day 5), 1-Month Post-Treatment (T₂), and 3-Months Post-Treatment (T₃). | The BPI evaluates the sensory-discriminative dimension of pain. It measures both pain intensity (worst, least, average, and current pain on a 0-10 scale) and pain interference-quantifying how much the facial pain disrupts seven functional domains of daily life (general activity, walking, mood, normal work, relationships, sleep, and enjoyment of life). It also tracks changes in the spatial distribution and trigger zones mapped on the BPI body outline chart. |
| Secondary | Change from Baseline in Emotional Distress and Psychological Co-morbidities via the Hospital Anxiety and Depression Scale (HADS) | Baseline (T₀), 1-Month Post-Treatment (T₂), and 3-Months Post-Treatment (T₃). | The HADS is a 14-item self-rating scale used to isolate and quantify levels of anxiety (HADS-A, 7 items) and depression (HADS-D, 7 items) triggered by prolonged exposure to chronic, severe pain. Each item is scored from 0 to 3, yielding separate subscale totals from 0 to 21. Higher scores indicate greater psychological distress (scores ≥ 11 signify severe, clinically relevant states). |
| Secondary | Change from Baseline in Health-Related Quality of Life via the Quality of Life Pain Scale (QoLp) | Baseline (T₀), 1-Month Post-Treatment (T₂), and 3-Months Post-Treatment (T₃). | The QoLp scale evaluates the broader functional, social, and economic toll of refractory Trigeminal Neuralgia on the patient's well-being. It measures multi-item domains including physical independence, social integration, occupational capability, and cognitive clarity under chronic pain conditions. |
| Secondary | Patient Global Impression of Clinical Improvement via the Patient Global Impression of Change (PGIC) Scale | Immediate Post-Treatment (T₁, Day 5), 1-Month Post-Treatment (T₂), and 3-Months Post-Treatment (T₃). | The PGIC is a single-item, 7-point categorical scale capturing the patient's holistic self-assessment of the overall shift in their medical condition since the start of the accelerated rTMS therapy. Scores range from 1 ("Very Much Improved") to 7 ("Very Much Worse"). A successful clinical response is defined as achieving a rating of 1 or 2. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908420
GET https://conductscience.org/api/trials/v1/NCT07908420/registered